Drug delivery systems struggle to penetrate fibrotic tumor regions where lipid‐laden TAMs reside, whereas heterogeneity in SR expression, such as variable CD206 or MARCO levels across metastases, limits nanoparticle precision. The gene discussed is MRC1; the disease is neoplasm.